Wind tunnel testing of low-drag airfoils

Results are presented for the measured performance recently obtained on several airfoil concepts designed to achieve low drag by maintaining extensive regions of laminar flow without compromising high-lift performance. The wind tunnel results extend from subsonic to transonic speeds and include boundary-layer control through shaping and suction. The research was conducted in the NASA Langley 8-Ft Transonic Pressure Tunnel (TPT) and Low Turbulence Pressure Tunnel (LTPT) which have been developed for testing such low-drag airfoils. Emphasis is placed on identifying some of the major factors influencing the anticipated performance of low-drag airfoils

Afatinib for the Treatment of \u3cem\u3eEGFR\u3c/em\u3e Mutation-Positive NSCLC: A Review of Clinical Findings

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of care in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). The availability of several EGFR tyrosine kinase inhibitors approved for use in the first-line or later settings in NSCLC warrants an in-depth understanding of the pharmacological properties of, and clinical data supporting, these agents. The second-generation, irreversible ErbB-family blocker, afatinib, has been extensively studied in the context of EGFRm+ NSCLC. Results from the LUX-Lung 3 and 6 studies showed that afatinib was more active and better tolerated than chemotherapy in patients with tumors harboring EGFR mutations. Subanalysis of these trials, along with real-world data, indicates that afatinib is active in patients with certain uncommon EGFR mutations (S768I/G719X/L861Q) as well as common mutations (Del19/L858R), and in patients with active brain metastases. In LUX-Lung 7, a head-to-head phase IIb trial, afatinib improved progression-free survival and time-to-treatment failure versus the first-generation reversible EGFR tyrosine kinase inhibitor, gefitinib, albeit with a higher incidence of serious treatment-related adverse events. Nevertheless, afatinib is generally well tolerated, and adverse events are manageable through supportive care and a well-defined tolerability-guided dose adjustment scheme. In this review, we provide a detailed overview of the pharmacology, efficacy, and safety of afatinib, discuss treatment sequencing strategies following emergence of different resistance mechanisms, and shed light on the economic impact of afatinib. We also provide a comparison of afatinib with the available EGFR tyrosine kinase inhibitors and discuss its position within treatment strategies for patients with EGFRm+ NSCLC

Test report for single event effects of the 80386DX microprocessor

The Jet Propulsion Laboratory Section 514 Single Event Effects (SEE) Testing and Analysis Group has performed a series of SEE tests of certain strategic registers of Intel's 80386DX CHMOS 4 microprocessor. Following a summary of the test techniques and hardware used to gather the data, we present the SEE heavy ion and proton test results. We also describe the registers tested, along with a system impact analysis should these registers experience a single event upset

The Effects of Hydropower Development at the Brandon Road Dam on Downstream Dissolved Oxygen Resources

published or submitted for publicationis peer reviewedOpe

The Effects of Hydropower Development at the Dresden Island Dam on Downstream Dissolved Oxygen Resources

published or submitted for publicationis peer reviewedOpe

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs.

A number of important drugs used to treat cancer-many of which serve as the backbone of modern chemotherapy regimens-have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice

Question Asking Strategies of Aphasic and Non-Brain-Damaged Subjects

TB

Neurophysiology

Contains reports on twenty research projects.Bell Laboratories (Grant)National Institutes of Health (Grant 5 R01 EY01149-03S2)National Institutes of Health (Grant 5 TO1 EY00090-04)National Institutes of Health (Grant 5 RO1 NS12307-03)National Institutes of Health (Grant K04 NS00010)National Multiple Sclerosis Society (Grant RG-1133-A-1)Health Sciences Fund (Grant 78-10

Portfolio Vol. VI N 1

Wyman, John. Mrs. Brannon\u27s Bathtub . Prose. 1. Holbrook, Harold R. Sonnet . Poem. 7. Hayne, Barbara. Prayer of A Youth . Poem. 7. Egger, Ellen. An Evening . Poem. 7. Cuninggim, Merrimon. Lambda Pi Beta Mu . Prose. 9. Willett, Thelma. White Rosebuds . Poem. 11. Willett, Thelma. Span of A Life in Mine . Poem. 11. Willett, Thelma. Seventeen . Poem. 11. Willett, Thelma. Ave Atque Vale . Poem. 11. Willett, Thelma. The Ashes of Letters . Poem. 11. Miller, Albert. ...To One I Have Known and Loved . Prose. 12. Wyman, John. Browning the Artist . Prose. 14. Brannon, Pat. Revolution . Poem. 18. Forsberg, Nancy. Unnamed. Poem. 18. Kearns, Carolyn. A Co-Ed\u27s Wish . Poem. 18. Goetz, Marilyn. Fate\u27s Fury . Prose. 19. Harvey, Richard. Man Who Ate the Cheesecake . Prose. 21. Spike, Robert. Mechanikos . Poem. 22. Stodghill, Patricia. Anodyne . Poem. 23. Ladd, Donald. Torch-Light . Poem. 23